IRIS
SANTORO, Armando
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 35.523
AS - Asia 22.040
EU - Europa 6.816
SA - Sud America 4.467
AF - Africa 1.218
Continente sconosciuto - Info sul continente non disponibili 45
OC - Oceania 37
AN - Antartide 1
Totale 70.147
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 34.772
SG - Singapore 13.993
BR - Brasile 3.678
CN - Cina 2.972
VN - Vietnam 2.297
FI - Finlandia 1.407
IE - Irlanda 1.125
IT - Italia 866
NG - Nigeria 810
DE - Germania 732
HK - Hong Kong 651
FR - Francia 649
CA - Canada 479
GB - Regno Unito 453
IN - India 425
NL - Olanda 371
SE - Svezia 317
AR - Argentina 294
TR - Turchia 281
BD - Bangladesh 218
IQ - Iraq 196
RU - Federazione Russa 180
MX - Messico 156
IL - Israele 144
EC - Ecuador 138
ZA - Sudafrica 115
ID - Indonesia 114
JP - Giappone 109
PL - Polonia 103
UA - Ucraina 97
BE - Belgio 96
CO - Colombia 96
PK - Pakistan 85
ES - Italia 81
CL - Cile 78
MA - Marocco 77
UZ - Uzbekistan 66
VE - Venezuela 62
SA - Arabia Saudita 54
PY - Paraguay 53
PH - Filippine 46
JO - Giordania 40
TN - Tunisia 37
EG - Egitto 35
RO - Romania 35
IR - Iran 34
AE - Emirati Arabi Uniti 33
CZ - Repubblica Ceca 33
AT - Austria 32
DZ - Algeria 32
KE - Kenya 32
LT - Lituania 32
AU - Australia 31
KR - Corea 29
UY - Uruguay 29
MY - Malesia 28
NP - Nepal 25
DO - Repubblica Dominicana 24
KZ - Kazakistan 24
OM - Oman 23
PE - Perù 23
AZ - Azerbaigian 22
CH - Svizzera 22
A2 - ???statistics.table.value.countryCode.A2??? 21
EU - Europa 21
BG - Bulgaria 20
ET - Etiopia 18
HU - Ungheria 18
TH - Thailandia 18
GR - Grecia 16
JM - Giamaica 16
LB - Libano 15
HN - Honduras 14
PT - Portogallo 14
SN - Senegal 14
CR - Costa Rica 13
NO - Norvegia 13
BY - Bielorussia 12
PA - Panama 12
TW - Taiwan 12
AL - Albania 11
AM - Armenia 11
BO - Bolivia 11
KG - Kirghizistan 11
RS - Serbia 10
SI - Slovenia 10
BH - Bahrain 9
HR - Croazia 9
KW - Kuwait 9
PS - Palestinian Territory 9
CG - Congo 8
CI - Costa d'Avorio 8
DK - Danimarca 8
LV - Lettonia 8
LY - Libia 8
NI - Nicaragua 8
SY - Repubblica araba siriana 8
TT - Trinidad e Tobago 8
EE - Estonia 7
LK - Sri Lanka 7
Totale 70.036
Salva come PNG Salva come JPEG
Città #
Singapore 6.500
Wilmington 5.545
Chandler 4.578
The Dalles 2.236
San Mateo 2.028
Ashburn 1.927
Dallas 1.726
Ann Arbor 1.547
Shanghai 1.468
Helsinki 1.398
Dublin 1.117
San Jose 1.079
Leawood 944
Princeton 913
Lawrence 912
Boardman 838
Benin City 805
Ho Chi Minh City 781
New York 676
Beijing 624
Hong Kong 602
Hanoi 553
Woodbridge 516
Paris 514
Fairfield 512
Amsterdam 329
São Paulo 304
Toronto 301
Milan 278
Los Angeles 226
Seattle 225
London 224
Kocaeli 180
Columbus 173
San Diego 166
Santa Clara 164
Council Bluffs 159
Rio de Janeiro 132
Phoenix 123
Norwalk 119
Da Nang 111
Haiphong 96
Belo Horizonte 93
Orem 93
Brussels 85
Warsaw 85
Tokyo 82
Falkenstein 79
Pune 78
Falls Church 74
Montreal 70
Baghdad 67
Chennai 65
Brasília 63
Curitiba 63
Tashkent 63
Redwood City 60
Brooklyn 58
Porto Alegre 58
Munich 57
Johannesburg 56
Guayaquil 55
Naples 55
Moscow 54
Dhaka 50
Monmouth Junction 50
Campinas 48
Frankfurt am Main 46
Hải Dương 46
Manchester 46
Mexico City 45
Biên Hòa 43
Chicago 42
Abbiategrasso 39
Erbil 38
Salvador 38
Buffalo 37
Redmond 37
San Francisco 37
Amman 36
Stockholm 36
Atlanta 35
Boston 35
Goiânia 35
Mumbai 34
Hillsboro 33
Istanbul 33
Charlotte 32
Denver 32
Quito 32
Thái Bình 32
Fortaleza 31
Guarulhos 31
Santiago 31
Des Moines 29
Houston 29
Assago 28
Asunción 28
Andover 27
New Delhi 27
Totale 46.470
Salva come PNG Salva come JPEG
Nome #
Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis 171
KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL) 164
Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer 158
18F-FDG PET and CT scan in the pre-operative evaluation of colorectal liver metastases treated with chemotherapy 156
An exploratory biomarker study in metastatic tumors from colorectal cancer patients treated with bevacizumab 154
18F-FDG pet does not improve contrast enhanced CT scan sensitivity in the evaluation of liver metastases after chemotherapy 148
A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma 142
Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases 136
A reduced dose of fluconazole as primary antifungal prophylaxis is not associated with increased risk of invasive fungal infections after allogenic stem call transplantation from a HLA identical sibling 134
A PHASE 1 SAFETY STUDY OF ONCOFID-P-B ADMINISTERED FOR 12 CONSECUTIVE WEEKS IN BCG UNRESPONSIVE/INTOLERANT PATIENTS WITH BLADDER CARCINOMA IN SITU (CIS): PRELIMINARY RESULTS 133
A Case of Pulmonary Sarcoidosis during First-Line Targeted Therapy with Dabrafenib Plus Trametinib in BRAF V600E-Mutated Metastatic Melanoma 132
Gene methylation in pleural mesothelioma : Correlations with clinico-pathological features and patient’s follow-up 132
Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases 132
BMS-986148, an anti-mesothelin antibody-drug conjugate (ADC), alone or in combination with nivolumab demonstrates clinical activity in patients with select advanced solid tumors 132
Role of consolidation RT to bulky lesions of advanced Hodgkin lymphoma: results of FIL HD0801 trial 131
A new human cell line, PDSS-26, from poorly differentiated synovial sarcoma, with unique chromosomal anomalies 130
A phase I clinical and pharmacokinetic study evaluating vinflumine in combination with epirubicin as first-line treatment in metastatic breast cancer 128
Metastasis of hepatocellular carcinoma to the heart: A case report and review of the literature 127
A Phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small cell lung cancer. 126
A circulating miRNA signature to implement diagnostic imaging analysis in young early-stage breast cancer patients 125
Carbon-11-methionine PET-CT as an imaging biomarker in brain gliomas eligible for surgery 124
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma 123
Cerebrospinal fluid tumor DNA for liquid biopsy in glioma patients’ management: close to clinic 121
Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study 120
Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study 119
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study 119
A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial 119
Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme 119
A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer 118
Biological characteristics and long-term outcomes in node-negative breast cancer 118
A. Micrometastasis in sentinel (SLN) and non sentinel lymph nodes of breast cancer: an update including clinico-pathologic impact and survaival 117
Initial chemotherapy for primary resectable large-cell lymphoma of the stomach 116
VINORELBINE (V) IN PEMETREXED-PRETREATED PATIENTS (PTS) WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) 116
Assessment of prognostic factors in patients with metastatic epidural spinal cord compression (MESCC) from solid tumor after surgery plus radiotherapy: a single institution experience 116
High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid 115
Tivantinib for hepatocellular carcinoma 115
Tivantinib for Second-line Treatment of Advanced MET-High Hepatocellular Carcinoma: A Phase 3, Randomized, Placebo-Controlled Study (METIV-HCC) 114
A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients with Advanced Hepatocellular Carcinoma 113
An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers 112
Primary refractory and early-relapsed Hodgkin's lymphoma : strategies for therapeutic targeting based on the tumour microenvironment 111
Alternating drug combinations in the treatment of advanced Hodgkin's disease. 109
Biomarkers in Hepatocellular Carcinoma-Letter 109
Outcome appraisal of patients with limited brain metastases (BMs) from non small cell lung cancer (NSCLC) treated with different local therapeutic strategies: a single institute evaluation. 108
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma 108
COVID-19 and liver cancer clinical trials: not everything is lost 107
. The level of HER2/neu amplification may have a correlation with some relevant histopathologcal features of early stage breast cancer 107
A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies 106
Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up 106
Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome 106
Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy 105
A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis 105
Pharmacological inactivation of DNA repair to improve response to immunotherapy: The Arethusa trial in metastatic colorectal cancer 105
Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with solid tumors 105
Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC) 104
Clinical Effects of Driver Somatic mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With allogeneic Hematopoietic Stem-Cell Transplantation 104
Superiority of CHOI vs RECIST criteria in evaluating outcome of advanced soft tissue sarcoma (STS) patients treated with sorafenib 104
Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer 103
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma 103
Treatment of malignant pleural mesothelioma: current status and future directions 103
Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma 102
Cyclic delivery of MOPP and ABVD combinations in Stage IV Hodgkin's disease: rationale, background studies, and recent results. 102
Advanced colorectal liver metastases and surgery after preoperative chemotherapy : is response-based selection enough? 102
Survival outcome and prognostic factors after pulmonary metastasectomy in sarcoma patients 102
Anatomic location of breast cancer micrometastasis in sentinel lymph node predicts axillary status 101
Addition of temozolomide to radiotherapy for treatment of newly diagnosed anaplastic gliomas 101
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications 101
A monocentric retrospective analysis of TILs and AR as hints for prognosis definition in TNBC 101
Adjuvant volumetric modulated arc therapy compared to 3D conformal radiation therapy for newly diagnosed soft tissue sarcoma of the extremities: outcome and toxicity evaluation 100
Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. 100
Checkpoint inhibitors as treatment for malignant gliomas: "A long way to the top" 100
Utility of 18F-FDG PET and contrast-enhanced CT scan in the assessment of residual liver metastasis from colorectal cancer following adjuvant chemotherapy 100
Advances in the biology of malignant pleural mesothelioma 100
Hypofractionated radiation therapy (HFRT) versus conventional fractionated radiation therapy (CRT) for newly diagnosed glioblastoma patients. A propensity score matched analysis. 99
Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study 99
Hypofractionation with simultaneous boost in breast cancer patients receiving adjuvant chemotherapy: A prospective evaluation of a case series and review of the literature 98
Imatinib mesylate in desmoplastic small round cell tumour 98
High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant 97
A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Circulating Tumor DNA 96
Short schedule of cisplatin and vinorelbine: A dose-finding study in non-small-cell lung cancer 96
Neutrophil to Lymphocyte Ratio (NLR) as predictive factor in patients with metastatic soft tissue sarcoma (STS) treated with trabectedin (T). 96
A Comparative Study of Methyl-BEAMing and Droplet Digital PCR for MGMT Gene Promoter Hypermethylation Detection 95
A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer 95
PHASE II STUDY OF THE COMBINATION OF BEVACIZUMAB PLUS PEMETREXED AND CARBOPLATIN AS FIRST-LINE THERAPY IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) 95
A. Micrometastasis in sentinel (SLN) and non sentinel lymph nodes of breast cancer: an update including clinico-pathologic impact and survaival 95
Clinical relevance of clonal hematopoiesis in persons aged ≥80 years 95
Activity of single agent vinorelbine in pretreated non-Hodgkin's lymphoma 94
Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non-Small-Cell Lung Cancer. 94
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer 94
AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients 94
Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach 94
Cardioprotection with nebivolol in patients undergoing anthracyclines: a randomized placebo-controlled trial 93
Dual PI3K/ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulation 93
Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkin's lymphoma. Assessment of risk of toxicity and secondary cancer induction 93
Adjuvant Treatment of High-Risk, Radically Resected Gastric Cancer Patients With 5-Fluorouracil, Leucovorin, Cisplatin, and Epidoxorubicin in a Randomized Controlled Trial. 93
Anthracycline analogues in advanced soft tissue sarcomas. Two EORTC randomized phase II studies of adriamycin vs carminomycin and 4'-epiadriamycin 93
A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer 93
Clinical implications of immunohistochemical assessment of somatostatin receptors subtype 2 and 5 in the diagnostic and therapeutic management of gastro-entero-pancreatic neuroendocrine tumours 92
DEXAMETHASONE, GRANISETRON, OR BOTH FOR THE PREVENTION OF NAUSEA AND VOMITING DURING CHEMOTHERAPY FOR CANCER 92
Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis 92
Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography 92
Totale 11.105
Salva come PNG Salva come JPEG
Categoria #
all - tutte 479.707
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 479.707
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.469 0 0 0 0 0 0 0 0 0 1.345 90 1.034
2021/20225.041 372 72 123 1.102 86 83 202 733 426 556 1.051 235
2022/202312.822 2.015 413 1.233 1.408 1.155 1.077 32 1.083 2.225 1.121 908 152
2023/20246.772 616 733 1.518 243 195 721 323 371 87 140 697 1.128
2024/202510.267 245 192 54 176 234 1.188 534 1.208 1.458 2.606 1.160 1.212
2025/202625.616 4.180 1.970 1.856 2.950 755 1.183 8.091 1.656 1.664 1.311 0 0
Totale 70.887